Literature DB >> 23161571

Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension.

Christine Veith1, Sigrid Schmitt, Florian Veit, Bhola Kumar Dahal, Jochen Wilhelm, Walter Klepetko, Gabriel Marta, Werner Seeger, Ralph Theo Schermuly, Friedrich Grimminger, Hossein A Ghofrani, Ludger Fink, Norbert Weissmann, Grazyna Kwapiszewska.   

Abstract

Chronic alveolar hypoxia induces vascular remodeling processes in the lung resulting in pulmonary hypertension (PH). However, the mechanisms underlying pulmonary remodeling processes are not fully resolved yet. To investigate functional changes occurring during hypoxia exposure we applied 2DE to compare protein expression in lungs from mice subjected to 3 h of alveolar hypoxia and those kept under normoxic conditions. Already after this short-time period several proteins were significantly regulated. Subsequent analysis by MALDI-MS identified cofilin as one of the most prominently upregulated proteins. The regulation was confirmed by western blotting and its cellular localization was determined by immunohisto- and immunocytochemistry. Interestingly, enhanced cofilin serine 3 phosphorylation was observed after short-term and after chronic hypoxia-induced PH in mice, in pulmonary arterial smooth muscle cells (PASMC) from monocrotaline-induced PH in rats, in lungs of idiopathic pulmonary arterial hypertension patients and in hypoxic or platelet-derived growth factor BB-treated human PASMC. Furthermore, elevated cofilin phosphorylation was attenuated by curative treatment of monocrotaline-induced PH in rats and hypoxia-induced PH in mice with the PDGF-BB receptor antagonist imatinib. In conclusion, short-term hypoxic exposure induced prominent changes in lung protein regulation. These very early changes allowed us to identify potential triggers of PH. Thus, respective 2DE analysis can lead to the identification of new target proteins for the possible treatment of PH.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23161571     DOI: 10.1002/pmic.201200206

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

Review 1.  Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension.

Authors:  Christine Veith; Ralph T Schermuly; Ralf P Brandes; Norbert Weissmann
Journal:  J Physiol       Date:  2015-09-30       Impact factor: 5.182

Review 2.  Hypoxia and the modulation of the actin cytoskeleton - emerging interrelations.

Authors:  Anke Zieseniss
Journal:  Hypoxia (Auckl)       Date:  2014-03-25

3.  Retinoblastoma protein (Rb) links hypoxia to altered mechanical properties in cancer cells as measured by an optical tweezer.

Authors:  S Khakshour; M P Labrecque; H Esmaeilsabzali; F J S Lee; M E Cox; E J Park; T V Beischlag
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

4.  Proteome Investigation of Rat Lungs subjected to Ex Vivo Perfusion (EVLP).

Authors:  Valentina Roffia; Antonella De Palma; Caterina Lonati; Dario Di Silvestre; Rossana Rossi; Marco Mantero; Stefano Gatti; Daniele Dondossola; Franco Valenza; Pierluigi Mauri; Francesco Blasi
Journal:  Molecules       Date:  2018-11-22       Impact factor: 4.411

5.  Decreased collagen VI in the tunica media of pulmonary vessels during exposure to hypoxia: a novel step in pulmonary arterial remodeling.

Authors:  Marie Žaloudíková; Adam Eckhardt; Richard Vytášek; Jiří Uhlík; Tomáš Novotný; Lucie Bačáková; Jana Musílková; Václav Hampl
Journal:  Pulm Circ       Date:  2019 Jul-Sep       Impact factor: 3.017

6.  Hypoxia modulates fibroblastic architecture, adhesion and migration: a role for HIF-1α in cofilin regulation and cytoplasmic actin distribution.

Authors:  Melanie Vogler; Sabine Vogel; Sabine Krull; Katja Farhat; Pia Leisering; Susanne Lutz; Christina M Wuertz; Dörthe M Katschinski; Anke Zieseniss
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.